Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Curtis A. Lachowiez, Vishvaas I Ravikumar, Jad Othman, Jenny O'Nions, Daniel T Peters, Christine McMahon, Ronan Swords, Rachel Cook, Jennifer N. Saultz, Jeffrey W. Tyner, Richard James Dillon, Joshua F. Zeidner, Daniel A. Pollyea

Blood blood.2024026925.

https://doi.org/10.1182/blood.2024026925

Published: 2024

Includes: Supplemental data

Journal Articles

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Blood (2023) 142 (Supplement 1): 3474.

https://doi.org/10.1182/blood-2023-173162

Published: 2023

Journal Articles

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood (2023) 142 (Supplement 1): 1515.

https://doi.org/10.1182/blood-2023-191166

Published: 2023

Journal Articles

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

Blood (2023) 142 (Supplement 1): 978.

https://doi.org/10.1182/blood-2023-179527

Published: 2023

Journal Articles

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Blood (2023) 142 (Supplement 1): 109.

https://doi.org/10.1182/blood-2023-173855

Published: 2023

Journal Articles

A Phase I/II Study to Investigate the Addition of Venetoclax to Dasatinib and Steroids in Patients with Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): The Venda Trial, in Progress

Jessica T. Leonard, Rachel Cook, Laura F. Newell, Arpita Gandhi, Ronan T. Swords, Christopher A. Eide, Brandon Hayes-Lattin, Kara Johnson, Elie Traer, Stephen E. Kurtz, Jennifer N. Saultz, Cristina Tognon, Jeffrey W Tyner, Curtis A. Lachowiez

Blood (2023) 142 (Supplement 1): 1512.

https://doi.org/10.1182/blood-2023-188313

Published: 2023

Journal Articles

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

Blood (2023) 142 (Supplement 1): 5762.

https://doi.org/10.1182/blood-2023-188311

Published: 2023

Journal Articles

The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist

Jennifer N. Saultz, Daniel Bottomly, Faith Burns, Kaelan Byrd, Yoko Kosaka, Shannon K. McWeeney, Stephen E. Kurtz, Guang Fan, Andy Kaempf, Karen McGovern, Lei Wang, Marta Sanchez-Martin, Dan S Kaufman, Evan F. Lind, Jeffrey W. Tyner

Blood (2022) 140 (Supplement 1): 3071–3072.

https://doi.org/10.1182/blood-2022-163166

Published: 2022

Journal Articles

Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Rashmi Khanal, Jennifer N. Saultz, Umar Farooq, Sunita Nathan, Amitkumar Mehta, Ayad Hamdan, Lawrence E. Morris, Jr., Houston Holmes, Lauren C. Pinter-Brown, John K.C. Lim, Amanda Conerty, Heather Raymon, Peter Flynn, Anita G. Seto, Joseph J. Maly

Blood (2022) 140 (Supplement 1): 12742–12743.

https://doi.org/10.1182/blood-2022-159282

Published: 2022

Journal Articles

Breakthrough CMV Viremia Outcomes of Letermovir Prophylaxis in Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide

Arthur Nguyen, Joseph S Bubalo, Jennifer N. Saultz, Brandon Hayes-Lattin, Andy Chen, Rachel J. Cook, Arpita Gandhi, Jessica Leonard, Richard T. Maziarz, Yazan Migdady, Eneida R. Nemecek, Levanto Schachter

Blood (2022) 140 (Supplement 1): 12856–12858.

https://doi.org/10.1182/blood-2022-156011

Published: 2022

Journal Articles

Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Alice S. Mims, Melhem Solh, Jennifer N. Saultz, Uma Borate, Naveen Pemmaraju, Gautam Borthakur, Gail J. Roboz, Ben Powell, Bernice Matusow, Jason Halladay, Shireen Vali, Chelsea L. Hope, Madan G. Kundu, Ching Hsu, Paul Watkins, Chao Zhang, Jackie M. Walling, Athanasios C. Tsiatis, Amy E. DeZern

Blood (2021) 138 (Supplement 1): 3420.

https://doi.org/10.1182/blood-2021-152040

Published: 2021

Journal Articles

FLT3-Mutated Acute Myeloid Leukemia Using a Novel Regimen of Gemtuzumab Ozogamicin and Midostaurin in Combination with Standard Cytarabine and Daunorubicin Induction Therapy

Uma Borate, Andy Kaempf, Jessica Minnier, Shikha Misra, Shaun Goodyear, Gabrielle Meyers, Jennifer N. Saultz, Elie Traer, Ronan Swords, Rachel J. Cook, Sammantha Avaylon, Melissa Mackey, Brianna Norris, Roland B. Walter

Blood (2021) 138 (Supplement 1): 1269.

https://doi.org/10.1182/blood-2021-152791

Published: 2021

Journal Articles

Novel Combination Therapy of Venetoclax and Ruxolitinib in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia

Uma Borate, Jennifer N. Saultz, Andy Kaempf, Jessica Minnier, Cristina E. Tognon, Stephen E. Kurtz, Christopher A. Eide, Prapti A. Patel, Yazan F. Madanat, Peter Clement, Sammantha Avaylon, Shikha Misra, Brian J. Druker, Jeffrey W. Tyner

Blood (2021) 138 (Supplement 1): 2333.

https://doi.org/10.1182/blood-2021-152903

Published: 2021

Journal Articles

Aryl Hydrocarbon Receptor (AHR) Gene Expression in AML Is Associated with FLT3-ITD+ AML and HLA-E Induced Immune Resistance Reversed By Ik-364

Jennifer N. Saultz, Evan F. Lind, Jeffrey W. Tyner, Kaelan Byrd, Shannon K. McWeeney, Yoko Kosaka, Karen McGovern, Lei Wang, Marta Sanchez-Martin

Blood (2021) 138 (Supplement 1): 1161.

https://doi.org/10.1182/blood-2021-147589

Published: 2021

Journal Articles

Early Infection after Allogeneic Transplant Increases NRM without Influencing Relapse Rate

Jennifer N Saultz, DO, Kaycee Moshofsky, BS, Andy Kaempf, MS, Guang Fan, MD PhD, Gabrielle Meyers, Rachel J. Cook, MD, Richard T. Maziarz, MD, Peggy Appel, Francisco Tria, MD, Staci Williamson, MS

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-142048

Published: 2020

Journal Articles

Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function

Blood (2018) 132 (17): 1792–1804.

https://doi.org/10.1182/blood-2018-03-838474

Published: 2018

Includes: Supplemental data

Journal Articles

Headache Prevalence Following Recovery from TTP and aHUS: A Single-Center, Cross Sectional Cohort Survey Study

Jennifer N Saultz, DO, Haifeng M Wu, MD, Spero R Cataland, MD

Blood (2014) 124 (21): 4826.

https://doi.org/10.1182/blood.V124.21.4826.4826

Published: 2014

NARROW

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

A Phase I/II Study to Investigate the Addition of Venetoclax to Dasatinib and Steroids in Patients with Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): The Venda Trial, in Progress

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist

Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Breakthrough CMV Viremia Outcomes of Letermovir Prophylaxis in Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide

Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

FLT3-Mutated Acute Myeloid Leukemia Using a Novel Regimen of Gemtuzumab Ozogamicin and Midostaurin in Combination with Standard Cytarabine and Daunorubicin Induction Therapy

Novel Combination Therapy of Venetoclax and Ruxolitinib in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia

Aryl Hydrocarbon Receptor (AHR) Gene Expression in AML Is Associated with FLT3-ITD+ AML and HLA-E Induced Immune Resistance Reversed By Ik-364

Early Infection after Allogeneic Transplant Increases NRM without Influencing Relapse Rate

Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function

Headache Prevalence Following Recovery from TTP and aHUS: A Single-Center, Cross Sectional Cohort Survey Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only